Pharmacy Benefit Manager (PBM) Market 연구

그만큼 PBM market research is a crucial tool for comprehending the dynamics and trends of this industry. PBMs act as intermediaries in the healthcare system, assuming responsibility for managing prescription drug benefits for health plans, employers, and government programs.

그들은 약품 제조업체와 협상하여 약품 가격을 설정하고 약품 처방집을 작성하며 약국 네트워크를 감독하여 환자에게 효율적이고 비용 효과적인 약품 전달을 보장합니다. 따라서 헬스케어 서비스에 대한 수요가 지속적으로 증가함에 따라 이해관계자와 투자자들은 PBM 시장 조사에 많은 관심을 가져왔습니다.

약국 혜택 관리자(PBM) 시장 조사란 무엇입니까?

PBM 시장 조사에는 제약 산업과 관련된 데이터를 획득, 분석 및 이해하는 체계적인 접근 방식이 포함됩니다. 이 연구는 규모, 추세, 성장 잠재력, 규제 요구 사항, 경쟁 환경 및 소비자 선호도와 같은 시장의 현재 상태에 대한 유용한 통찰력을 제공하기 위한 것입니다. 또한 이는 업계를 유지하는 새로운 기회와 장애물을 정확히 찾아내는 데 도움을 주어 의사 결정자가 정보에 입각한 선택을 하고 지속적인 성공을 보장하는 효과적인 성장 전략을 개발할 수 있도록 합니다.

이러한 이유로 조직은 PBM 산업의 변화를 주도하는 요인에 대한 깊은 이해를 얻고 시장의 미래에 대한 귀중한 통찰력을 얻을 수 있습니다. 이 연구는 PBM 시장의 복잡하고 경쟁적인 환경을 헤쳐나가는 건강 보험, 고용주, 정부 기관, 제약 제조업체 및 기타 업계 이해관계자에게 특히 유용할 수 있습니다.

Pharmacy Benefit Manager PBM Market Research: How Leading Payers and Manufacturers Win

Pharmacy Benefit Manager PBM Market Research has become the decisive intelligence layer separating payers, manufacturers, and self-insured employers who optimize drug spend from those who absorb it. The pricing mechanics, rebate flows, and formulary control points inside PBMs are opaque by design. The firms that understand the mechanics gain leverage. The firms that do not, pay retail.

The market is consolidating around three vertically integrated players controlling roughly 80% of prescription claims volume in the United States: CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth). Each pairs PBM operations with a health plan, a specialty pharmacy, and a mail-order channel. That structural shift changes what intelligence is worth gathering and how to gather it.

Why Pharmacy Benefit Manager PBM Market Research Now Drives Net Price Strategy

Gross-to-net erosion has reordered the priorities of pharmaceutical commercial teams. List price means little. Net price after rebates, administrative fees, manufacturer-funded copay assistance, 340B chargebacks, and DIR fees is what determines launch economics and lifecycle returns.

The introduction of the Inflation Reduction Act’s Medicare price negotiation, the FTC’s interim reports on PBM vertical integration, and state-level transparency statutes in Ohio, California, and New York have changed what data is accessible and what behavior is defensible. Manufacturers conducting payer value story development now stress-test formulary positioning against a regulatory backdrop that did not exist five years ago.

According to SIS International Research, the most effective payer engagement programs treat the PBM pharmacy and therapeutics committee, the health plan medical director, and the employer benefits consultant as three distinct buyers requiring three distinct evidence packages, rather than a single audience reached through one value dossier.

The Intelligence Gaps Where Leading Firms Compete

Conventional PBM research relies on syndicated claims data and published formulary lists. That tells you what already happened. It does not tell you why a drug was placed at Tier 3 with prior authorization, what rebate threshold would move it to Tier 2, or which competing manufacturer offered a portfolio deal that locked the slot.

The firms that win the formulary work the negotiation chain through primary research. Structured B2B expert interviews with former PBM trade relations directors, current pharmacy directors at regional health plans, and consultants at Mercer, Aon, and WTW yield the contracting logic that claims data cannot.

Three intelligence gaps consistently separate leading commercial teams from the rest:

Rebate aggregator economics. Ascent (Express Scripts), Zinc (CVS), and Emisar (Optum) sit between manufacturers and PBMs, capturing fee structures that rarely appear in published contracts. Understanding the spread between manufacturer rebate and plan sponsor pass-through is foundational to net pricing strategy.

Specialty pharmacy steerage. Accredo, CVS Specialty, and BriovaRx route limited-distribution drugs through channels owned by the same enterprise that adjudicates the claim. Market access strategy now depends on understanding which therapies face mandatory steerage and which retain choice at the patient level.

Employer carve-out behavior. Self-insured employers above 5,000 lives are increasingly carving out specialty pharmacy or partnering with transparent PBM challengers like Navitus, Capital Rx, and SmithRx. Tracking which industries and benefits consultants drive carve-out adoption signals where traditional rebate models lose ground.

What Leading PBM Market Research Programs Look Like

The strongest programs combine four methodologies in sequence rather than running them as one-off studies.

KOL mapping at the PBM and health plan level identifies the actual decision-makers on national and regional P&T committees, separating titular reviewers from voting influencers. Patient journey mapping for specialty therapies traces the prior authorization, step therapy, and accumulator adjustment touchpoints that determine real-world adherence. HTA submission evidence gets refined through payer advisory boards before ICER reviews, not after. Real-world evidence generation is sequenced to support the second-line indication that drives the lifecycle case.

In structured expert interviews SIS International has conducted with senior pharmacy and medical directors across North America and Latin America, the consistent pattern is that formulary decisions made in the first 90 days post-launch are rarely revisited for 18 to 24 months, making pre-launch payer research the highest-leverage commercial investment in the lifecycle.

Comparing the PBM Models Manufacturers Now Negotiate Against

Source: SIS International Research analysis of public PBM filings and primary expert interviews

The Geographic Expansion of PBM Models

The PBM construct is no longer purely American. Brazil, Mexico, and parts of the Gulf are introducing PBM-style intermediaries as private health insurance penetration grows and specialty drug spend accelerates. SIS International’s mixed-methodology research in Brazilian healthcare, combining quantitative provider sampling with qualitative payer interviews, indicates that Latin American PBM adoption is following a different sequence than the US, with employer-led procurement preceding insurer consolidation rather than the reverse.

For multinational manufacturers, that sequence matters. Market access strategy in São Paulo cannot be ported from Chicago. The negotiation counterparty, the rebate norms, and the formulary governance differ at the structural level.

The SIS Approach to PBM Intelligence

SIS International’s healthcare practice combines B2B expert interviews with former PBM executives, payer advisory boards with active P&T committee members, KOL mapping across specialty therapeutic areas, and competitive intelligence on rebate structures and specialty pharmacy steerage. The work is built for commercial leadership decisions: launch sequencing, indication prioritization, gross-to-net forecasting, and contracting strategy ahead of biosimilar entry.

The Pharmacy Benefit Manager PBM Market Research that drives commercial outcomes is not a deck of formulary screenshots. It is the negotiation logic, the rebate math, and the buyer-by-buyer evidence package that determines whether a launch hits its net price target.

Where the Opportunity Compounds

The manufacturers and self-insured employers investing in deeper Pharmacy Benefit Manager PBM Market Research now are buying optionality. Optionality to negotiate against vertically integrated incumbents. Optionality to evaluate transparent challenger PBMs without ideological bias. Optionality to redesign benefits before the next renewal cycle locks in another three years of rebate dependency. The intelligence gap is the commercial advantage.

SIS 인터내셔널 소개

SIS 국제 정량적, 정성적, 전략 연구를 제공합니다. 우리는 의사결정을 위한 데이터, 도구, 전략, 보고서 및 통찰력을 제공합니다. 또한 인터뷰, 설문 조사, 포커스 그룹, 기타 시장 조사 방법 및 접근 방식을 수행합니다. 문의하기 다음 시장 조사 프로젝트를 위해.